These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7533152)

  • 1. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.
    Hüsler T; Lockert DH; Kaufman KM; Sodetz JM; Sims PJ
    J Biol Chem; 1995 Feb; 270(8):3483-6. PubMed ID: 7533152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
    Lockert DH; Kaufman KM; Chang CP; Hüsler T; Sodetz JM; Sims PJ
    J Biol Chem; 1995 Aug; 270(34):19723-8. PubMed ID: 7544344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
    Husler T; Lockert DH; Sims PJ
    Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
    Tomlinson S; Whitlow MB; Nussenzweig V
    J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59.
    Zhao XJ; Zhao J; Zhou Q; Sims PJ
    J Biol Chem; 1998 Apr; 273(17):10665-71. PubMed ID: 9553129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
    White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
    J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9.
    Ninomiya H; Sims PJ
    J Biol Chem; 1992 Jul; 267(19):13675-80. PubMed ID: 1377690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
    Chang CP; Hüsler T; Zhao J; Wiedmer T; Sims PJ
    J Biol Chem; 1994 Oct; 269(42):26424-30. PubMed ID: 7523406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.
    Ninomiya H; Stewart BH; Rollins SA; Zhao J; Bothwell AL; Sims PJ
    J Biol Chem; 1992 Apr; 267(12):8404-10. PubMed ID: 1373727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
    Lehto T; Meri S
    J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis.
    Tomlinson S; Wang Y; Ueda E; Esser AF
    J Immunol; 1995 Jul; 155(1):436-44. PubMed ID: 7541424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
    Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
    J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
    Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
    J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
    Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
    J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of human and rat CD59 to the terminal complement complexes.
    Lehto T; Morgan BP; Meri S
    Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
    Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the active site of CD59 with synthetic peptides.
    Nakano Y; Tozaki T; Kikuta N; Tobe T; Oda E; Miura N; Sakamoto T; Tomita M
    Mol Immunol; 1995 Mar; 32(4):241-7. PubMed ID: 7536892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
    Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
    Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.